These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 26211600)

  • 1. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
    Tefferi A; Kantarjian H; Rajkumar SV; Baker LH; Abkowitz JL; Adamson JW; Advani RH; Allison J; Antman KH; Bast RC; Bennett JM; Benz EJ; Berliner N; Bertino J; Bhatia R; Bhatia S; Bhojwani D; Blanke CD; Bloomfield CD; Bosserman L; Broxmeyer HE; Byrd JC; Cabanillas F; Canellos GP; Chabner BA; Chanan-Khan A; Cheson B; Clarkson B; Cohn SL; Colon-Otero G; Cortes J; Coutre S; Cristofanilli M; Curran WJ; Daley GQ; DeAngelo DJ; Deeg HJ; Einhorn LH; Erba HP; Esteva FJ; Estey E; Fidler IJ; Foran J; Forman S; Freireich E; Fuchs C; George JN; Gertz MA; Giralt S; Golomb H; Greenberg P; Gutterman J; Handin RI; Hellman S; Hoff PM; Hoffman R; Hong WK; Horowitz M; Hortobagyi GN; Hudis C; Issa JP; Johnson BE; Kantoff PW; Kaushansky K; Khayat D; Khuri FR; Kipps TJ; Kripke M; Kyle RA; Larson RA; Lawrence TS; Levine R; Link MP; Lippman SM; Lonial S; Lyman GH; Markman M; Mendelsohn J; Meropol NJ; Messinger Y; Mulvey TM; O'Brien S; Perez-Soler R; Pollock R; Prchal J; Press O; Radich J; Rai K; Rosenberg SA; Rowe JM; Rugo H; Runowicz CD; Sandmaier BM; Saven A; Schafer AI; Schiffer C; Sekeres MA; Silver RT; Siu LL; Steensma DP; Stewart FM; Stock W; Stone R; Storb R; Strong LC; Tallman MS; Thompson M; Ueno NT; Van Etten RA; Vose JM; Wiernik PH; Winer EP; Younes A; Zelenetz AD; LeMaistre CA
    Mayo Clin Proc; 2015 Aug; 90(8):996-1000. PubMed ID: 26211600
    [No Abstract]   [Full Text] [Related]  

  • 2. US oncologists call for government regulation to curb drug price rises.
    McCarthy M
    BMJ; 2015 Jul; 351():h4063. PubMed ID: 26208848
    [No Abstract]   [Full Text] [Related]  

  • 3. Lowering the High Cost of Cancer Drugs--I.
    Braillon A
    Mayo Clin Proc; 2016 Mar; 91(3):397. PubMed ID: 26944245
    [No Abstract]   [Full Text] [Related]  

  • 4. In Reply--Lowering the High Cost of Cancer Drugs.
    Kantarjian H; Tefferi A
    Mayo Clin Proc; 2016 Mar; 91(3):401-3. PubMed ID: 26944248
    [No Abstract]   [Full Text] [Related]  

  • 5. Lowering the High Cost of Cancer Drugs--IV.
    Martenson JA
    Mayo Clin Proc; 2016 Mar; 91(3):400-1. PubMed ID: 26944247
    [No Abstract]   [Full Text] [Related]  

  • 6. Lowering the High Cost of Cancer Drugs--III.
    Attaran A; Mackey T; Beall R
    Mayo Clin Proc; 2016 Mar; 91(3):399-400. PubMed ID: 26944246
    [No Abstract]   [Full Text] [Related]  

  • 7. Overspending driven by oversized single dose vials of cancer drugs.
    Bach PB; Conti RM; Muller RJ; Schnorr GC; Saltz LB
    BMJ; 2016 Feb; 352():i788. PubMed ID: 26932932
    [No Abstract]   [Full Text] [Related]  

  • 8. News feature: Costly US anticancer drugs pose problems for doctors and patients.
    Charatan F
    BMJ; 2008 Jul; 337(7662):a778. PubMed ID: 18625596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paying a high price for cancer drugs.
    Lancet; 2015 Aug; 386(9992):404. PubMed ID: 26251376
    [No Abstract]   [Full Text] [Related]  

  • 10. Oncology drug pricing structure is broken.
    Hutchinson L
    Nat Rev Clin Oncol; 2015 Sep; 12(9):499. PubMed ID: 26309071
    [No Abstract]   [Full Text] [Related]  

  • 11. Cancer drugs in the United States: Justum Pretium--the just price.
    Kantarjian HM; Fojo T; Mathisen M; Zwelling LA
    J Clin Oncol; 2013 Oct; 31(28):3600-4. PubMed ID: 23650428
    [No Abstract]   [Full Text] [Related]  

  • 12. Oncology drug costs-the imaginary crisis?
    Turck R
    Ann Oncol; 2017 Feb; 28(2):427-431. PubMed ID: 27771612
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cost/benefit analysis of cancer drugs].
    Jordan B
    Med Sci (Paris); 2020 Nov; 36(11):1095-1097. PubMed ID: 33151876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs for cancer and copayments.
    Finlay I; Crisp N
    BMJ; 2008 Jun; 337(7660):a527. PubMed ID: 18595953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs are scarce as mix of programs aims to ease access.
    Brower V
    J Natl Cancer Inst; 2009 Oct; 101(19):1304-6. PubMed ID: 19755680
    [No Abstract]   [Full Text] [Related]  

  • 16. Medicare cost containment strategy targets several oncology drugs.
    Twombly R
    J Natl Cancer Inst; 2004 Sep; 96(17):1268-70. PubMed ID: 15339960
    [No Abstract]   [Full Text] [Related]  

  • 17. When will the U.S. flinch at cancer drug prices?
    Vanchieri C
    J Natl Cancer Inst; 2005 May; 97(9):624-6. PubMed ID: 15870428
    [No Abstract]   [Full Text] [Related]  

  • 18. The just price of cancer drugs and the growing cost of cancer care: oncologists need to be part of the solution.
    Pfister DG
    J Clin Oncol; 2013 Oct; 31(28):3487-9. PubMed ID: 24002517
    [No Abstract]   [Full Text] [Related]  

  • 19. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
    [No Abstract]   [Full Text] [Related]  

  • 20. Critical issue is rapidity of review of new drugs.
    Rodger A
    BMJ; 2008 Jul; 337(7662):a779. PubMed ID: 18625599
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.